BPTF Monoclonal Antibody

developmental stage:Abundantly expressed in the fetal brain. Present throughout the gray and white matter of the developing spinal cord at 18-22 gestational weeks. Expressed at low levels in adult brain and spinal cord and reexpressed in neurodegenerative diseases (at protein level).,domain:The second PHD-type zinc finger mediates binding to histone H3-K4Me3.,function:Histone-binding component of NURF (nucleosome-remodeling factor), a complex which catalyzes ATP-dependent nucleosome sliding and facilitates transcription of chromatin. Specifically recognizes H3 tails trimethylated on 'Lys-4' (H3-K4Me3), which mark transcription start sites of virtually all active genes. May also regulate transcription through direct binding to DNA or transcription factors.,miscellaneous:Highly susceptible to proteolysis.,PTM:Phosphorylation enhances DNA-binding. Phosphorylated upon DNA damage, probably by ATM or ATR.,sequence caution:Several sequencing errors in the N-terminal part.,sequence caution:Several sequencing errors.,similarity:Belongs to the PBTF family.,similarity:Contains 1 bromo domain.,similarity:Contains 1 DDT domain.,similarity:Contains 2 PHD-type zinc fingers.,subcellular location:In brains of Alzheimer disease patients, present in a subset of amyloid-containing plaques.,subunit:Interacts with MAZ. Interacts with KEAP1. Part of the nucleosome-remodeling factor (NURF) complex which consists of SMARCA1; BPTF; RBBP4 and RBBP7. Interacts with histone H3-K4Me3 and to a lesser extent with histone H3-K4Me2.,tissue specificity:Ubiquitously expressed, with highest levels in testis. Present in kidney, liver and brain. In the brain, highest levels are found in motor cortex (at protein level).,